DRI Capital earmarks $1.45B for drug-royalty buys

DRI Capital has raised $1.45 billion to buy up drug royalties, aiming for everything from approved products to Phase III development candidates. The firm has a history of snagging royalty streams, and it now owns royalties on such drugs as Remicade, Enbrel and Soliris. Report